GlassScriptPhysician profile
Amit Kumar Dulabh
NPI 1598085342
$1,234.75
in general payments reported to CMS, 2019-2025
14 companies · $157 in 2025
The $157 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $138 · 2021: $193 · 2022: $239 · 2023: $243 · 2024: $145 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $544.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $292.12 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Abbott Laboratories | $179.24 | 2021-2023 | Cardiomems, Id Now Instrument |
| Tris Pharma INC | $163.06 | 2020-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $98.33 | 2020-2023 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $94.80 | 2021-2024 | Qelbree, Qelbree |
| Corium, LLC | $75.19 | 2021-2023 | Azstarys |
| Collegium Pharmaceutical, INC. | $75.15 | 2025 | Jornay Pm |
| Pfizer INC. | $46.76 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.53 | 2020-2023 | |
| Shire North American Group INC | $44.43 | 2019 | |
| Sanofi Pasteur INC. | $42.35 | 2021-2024 | |
| Sobi, INC | $30.45 | 2019-2021 | |
| Biomarin Pharmaceutical INC. | $25.44 | 2024 | Voxzogo 1.2mg |
| Astrazeneca Pharmaceuticals LP | $20.90 | 2024 | Flumist Quadrivalent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Dulabh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.